eISSN: 2081-2833
ISSN: 2081-0016
Medycyna Paliatywna/Palliative Medicine
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
3/2020
vol. 12
 
Share:
Share:
abstract:
Original paper

Off-label drug use in palliative care in Poland

Tomasz Dzierżanowski
1
,
Tomasz Grądalski
2
,
Michał Graczyk
3
,
Marcin Janecki
4
,
Agnieszka Kluczna
1
,
Marta Szostakiewicz
5

  1. Pracownia Medycyny Paliatywnej, Zakład Medycyny Społecznej i Zdrowia Publicznego, Warszawski Uniwersytet Medyczny
  2. Hospicjum im. św. Łazarza w Krakowie
  3. Katedra Opieki Paliatywnej, Collegium Medicum w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu
  4. Zakład Medycyny i Opieki Paliatywnej Katedry Pielęgniarstwa, Wydział Nauk o Zdrowiu, Śląski Uniwersytet Medyczny w Katowicach
  5. Centrum Opieki Paliatywnej „Betania” w Opolu, Poradnia Medycyny Paliatywnej w Brzegu
Medycyna Paliatywna 2020; 12(3): 110–121
Online publish date: 2020/10/05
View full text Get citation
 
PlumX metrics:
Introduction
Off-label drug use is when a drug is used in indications, doses, forms, routes of administration, and in groups of patients not mentioned in the summary of product characteristics, or despite contraindications.

Aim
Research in the population of palliative care patients, for ethical reasons, is significantly limited, and even impossible, so drug use is often based on the clinician’s experience, predominant practice, or prevailing opinion. Off-label drug use may not bring the desired results, or may even harm the patient.

Material and methods
In this study, 304 reports on possible off-label use of medicines in Poland were collected. After rejecting erroneous, repetitive, or unfounded cases, 86 cases of off-label drug use in adults in palliative care were finally obtained for which the literature was reviewed and which were evaluated by a team of experts. Experts admitted to off-label use in two-thirds of the presented cases, and 37.1% of them – often or very often.

Results
Experts assessed nine of them as “necessary – no alternative” procedures. In this way, a list of off-label drug uses was created with the formulated recommendation, category of the necessity, level of evidence, and grade of recommendation. Frequent off-label drug use in palliative care results from the lack of alternative options, as well as the gap between clinical practice, the lack of clinical data, and the content of the summaries of product characteristics.

Conclusions
Legal changes are needed for the use of medicines based on clinical recommendations, in particular for procedures that are necessary and have no alternatives.

keywords:

palliative care, pharmacotherapy, off-label use

FEATURED PRODUCTS
BOOKS
Medycyna Paliatywna
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.